biphasic insulin aspart 70

**Biphasic insulin aspart 70** is a premixed recombinant insulin aspart analogue formulation developed by Novo Nordisk for treatment of diabetes mellitus. It contains 70% soluble rapid-acting insulin aspart and 30% protamine-crystallised insulin aspart, providing both prandial insulin coverage and a more prolonged intermediate insulin effect. Insulin aspart activates the insulin receptor, increasing peripheral glucose uptake and suppressing hepatic glucose production. The product has been marketed as NovoMix 70 and NovoRapid 70 Mix for adults with diabetes requiring insulin therapy.

Brand names

NovoMix 70NovoMix70NovoMix-70NovoRapid 70 MixNovoRapid70 MixNovoRapid-70 Mix

Other names

BIAsp 70BIAsp70BIAsp-70biphasic insulin aspart 70